Ribociclib plus Endocrine Therapy in Early Breast Cancer
Mar 20, 2024 · In this international, open-label, randomized, phase 3 trial, we randomly assigned patients with HR-positive, HER2-negative early breast cancer in a 1:1 ratio to receive ribociclib (at a...
Ribociclib plus Endocrine Therapy in Early Breast Cancer
Mar 21, 2024 · Ribociclib plus an NSAI significantly improved invasive disease-free survival among patients with HR-positive, HER2-negative stage II or III early breast cancer. (Funded by Novartis; NATALEE ClinicalTrials.gov number, NCT03701334.).
Ribociclib plus Endocrine Therapy in Early Breast Cancer
Jun 20, 2024 · Ribociclib plus Endocrine Therapy in Early Breast Cancer. N Engl J Med. 2024 Jun 20;390 (23):2220. doi: 10.1056/NEJMc2404917. Authors. Qian Li 1 , Yuanxuan Cai 1 , Jie Li 1. Affiliation. 1 Guangzhou Women and Children's Medical Center, Guangzhou, China [email protected]. PMID: 38899705. DOI: 10.1056/NEJMc2404917. Publication types. Letter.
Ribociclib plus Endocrine Therapy in Early Breast Cancer
Jun 19, 2024 · To the Editor: The recent NATALEE trial (March 21/28 issue) 1 provides compelling evidence of the efficacy of adjuvant ribociclib therapy among patients with breast cancer.
Ribociclib and endocrine therapy as adjuvant treatment in …
Jun 7, 2023 · Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial. Authors: Dennis J. Slamon, Daniil Stroyakovskiy, Denise A. Yardley, Chiun-Sheng Huang, Peter A. Fasching, John Crown, Aditya Bardia, ….
Ribociclib plus Endocrine Therapy in Early Breast Cancer
The 3-year regimen of ribociclib at a 400-mg starting dose plus an NSAI was not associated with any new safety signals. Conclusions Ribociclib plus an NSAI significantly improved invasive disease-free survival among patients with HR-positive, HER2 …
NATALEE Trial Long-Term Results on Ribociclib Combination Therapy …
Jan 25, 2024 · Invasive disease–free survival continued to be significantly improved for patients with hormone receptor–positive, HER2-negative, early-stage breast cancer who received the CDK4/6 inhibitor ribociclib plus a nonsteroidal aromatase inhibitor compared with a nonsteroidal aromatase inhibitor alone.
A phase III trial of adjuvant ribociclib plus endocrine therapy vs ...
Oct 21, 2024 · NATALEE assessed efficacy and tolerability of 3 years of adjuvant ribociclib plus NSAI compared with a nonsteroidal aromatase inhibitor (NSAI) alone in a broad population of patients with HR+/HER2− early breast cancer, including a select group without nodal involvement.
NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy …
May 26, 2019 · ADAPTcycle: Adjuvant dynamic marker-adjusted personalized therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer.
Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy …
May 21, 2024 · Lu YS, Im SA, Colleoni M, et al: Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+/HER2- advanced breast cancer in MONALEESA-7: A phase III randomized clinical trial. Clin Cancer Res 28:851-859, 2022